These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6990545)

  • 1. Properties of antithrombin III depleted plasma. I. Effect of heparin.
    Holmer E; Söderström G; Andersson LO
    Thromb Res; 1980 Jan 1-15; 17(1-2):113-24. PubMed ID: 6990545
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma.
    Andersson LO; Barrowcliffe TW; Holmer E; Johnson EA; Söderström G
    Thromb Res; 1979; 15(3-4):531-41. PubMed ID: 494159
    [No Abstract]   [Full Text] [Related]  

  • 3. Activation of factor X and prothrombin in antithrombin-III depleted plasma: the effects of heparin.
    Ofosu FA; Blajchman MA; Modi G; Cerskus AL; Hirsh J
    Thromb Res; 1981 Aug 15-Sep 1; 23(4-5):331-45. PubMed ID: 7324001
    [No Abstract]   [Full Text] [Related]  

  • 4. [The determination of heparin].
    Aiach M
    Ann Biol Clin (Paris); 1982; 40(6):645-50. PubMed ID: 7165134
    [No Abstract]   [Full Text] [Related]  

  • 5. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A differential effect of low-affinity heparin on the inhibition of thrombin and factor Xa by antithrombin.
    Nordenman B; Nordling K; Björk I
    Thromb Res; 1980 Feb 1-15; 17(3-4):595-600. PubMed ID: 7368180
    [No Abstract]   [Full Text] [Related]  

  • 7. Anticoagulant properties of heparin preparations from different animal sources with equivalent high affinity for antithrombin III.
    Nagasawa K; Uchiyama H
    J Biochem; 1984 Mar; 95(3):619-26. PubMed ID: 6725227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Substitution of antithrombin III by synthetic thrombin inhibitors].
    Hauptmann J; Brüggener E; Müller H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):550-5. PubMed ID: 6083925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma.
    Ofosu FA; Modi G; Cerskus AL; Hirsh J; Blajchman MA
    Thromb Res; 1982 Nov; 28(4):487-97. PubMed ID: 7164033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal human plasma contains a naturally occurring antagonist of activated factor X inhibitor (antithrombin III) activity.
    Yin ET; Salsgiver WJ; Tangen O
    Thromb Res; 1979; 15(3-4):557-61. PubMed ID: 494161
    [No Abstract]   [Full Text] [Related]  

  • 11. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombin-antithrombin III complexes as a measure of effective heparin treatment?].
    Meyer D; Tsakiris DA; Marbet GA
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1352-4. PubMed ID: 2678451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide.
    Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):89-99. PubMed ID: 4035370
    [No Abstract]   [Full Text] [Related]  

  • 14. Antithrombin III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells.
    Chan TK; Chan V
    Thromb Haemost; 1981 Aug; 46(2):504-6. PubMed ID: 7302889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III.
    Baruch D; Lindhout T; Wagenvoord R; Hemker HC
    Haemostasis; 1986; 16(2):71-81. PubMed ID: 3086193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombin activity of a fucan sulfate from the brown seaweed Ecklonia kurome.
    Nishino T; Aizu Y; Nagumo T
    Thromb Res; 1991 Jun; 62(6):765-73. PubMed ID: 1926066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography.
    Hoogendoorn H; Cerskus A; Ofosu F; Blajchman M; Hirsh J
    Thromb Res; 1980 Oct; 20(1):77-83. PubMed ID: 7209874
    [No Abstract]   [Full Text] [Related]  

  • 18. Distinction of two pathologic antithrombin III molecules: antithrombin III "Aalborg' and antithrombin III "Budapest'.
    Sørensen PJ; Sas G; Petó I; Blaskó G; Kremmer T; Samu A
    Thromb Res; 1982 May; 26(3):211-9. PubMed ID: 7112514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the molecular-weight-dependence of the anticoagulant activity of heparin.
    Thunberg L; Lindahl U; Tengblad A; Laurent TC; Jackson CM
    Biochem J; 1979 Jul; 181(1):241-43. PubMed ID: 486155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.
    Ofosu FA; Fernandez F; Gauthier D; Buchanan MR
    Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.